Poster Session III non-clinical populations of young people, which generally displayed the highest quality of evidence. Although of overall lower quality, this relationship was also evident in clinical populations of young people with mental health problems other than psychosis. Evidence for the role of anxiety in those at clinical risk high for psychosis or diagnosed with psychosis was less conclusive, with very few studies, of variable quality, identified. These studies provided mixed findings, with some evidence for a co-occurrence between anxiety and psychosis risk/disorder, but no clear evidence of a causal role for anxiety in the transition to psychotic disorder. The size of the associations with anxiety appeared to vary by psychotic experience, with moderate evidence for hallucinations and little evidence grandiosity or anhedonia. Paranoia has the strongest evidence for a relationship with anxiety. Most studies were cross-sectional with few longitudinal studies preventing clear conclusions on a causal role of anxiety. Discussion: Evidence suggests that anxiety and psychotic experiences may co-occur in young people. This relationship appears to be transdiagnostic and potentially specific to individual psychotic experiences. As a result, more studies focusing on specific psychotic symptoms and psychological mechanisms are needed. However, research must move beyond cross-sectional associations and test the potential contributory causal role of anxiety using prospective, experimental, and interventionist designs. Despite the unknown direction of causality, the notable associations of psychotic experiences and anxiety in child mental health services indicate that this relationship may be of clinical importance. Establishing higher quality research in clinical settings is essential. Testing the effect of treating anxiety on the severity of psychotic symptoms will inform early intervention.
non-clinical populations of young people, which generally displayed the highest quality of evidence. Although of overall lower quality, this relationship was also evident in clinical populations of young people with mental health problems other than psychosis. Evidence for the role of anxiety in those at clinical risk high for psychosis or diagnosed with psychosis was less conclusive, with very few studies, of variable quality, identified. These studies provided mixed findings, with some evidence for a co-occurrence between anxiety and psychosis risk/disorder, but no clear evidence of a causal role for anxiety in the transition to psychotic disorder. The size of the associations with anxiety appeared to vary by psychotic experience, with moderate evidence for hallucinations and little evidence grandiosity or anhedonia. Paranoia has the strongest evidence for a relationship with anxiety. Most studies were cross-sectional with few longitudinal studies preventing clear conclusions on a causal role of anxiety. Discussion: Evidence suggests that anxiety and psychotic experiences may co-occur in young people. This relationship appears to be transdiagnostic and potentially specific to individual psychotic experiences. As a result, more studies focusing on specific psychotic symptoms and psychological mechanisms are needed. However, research must move beyond cross-sectional associations and test the potential contributory causal role of anxiety using prospective, experimental, and interventionist designs. Despite the unknown direction of causality, the notable associations of psychotic experiences and anxiety in child mental health services indicate that this relationship may be of clinical importance. Establishing higher quality research in clinical settings is essential. Testing the effect of treating anxiety on the severity of psychotic symptoms will inform early intervention. Background: The most promising strategy in targeted prevention of psychotic disorders is to treat the at risk-symptoms in the pre-psychotic period. Although high risk-symptoms for psychotic disorder are common in adolescence and associated with a marked reduction in functioning, the evidence base required to guide effective interventions for adolescents at risk and even first-episode psychosis is limited. The clinicians from the early intervention center in Zurich have developed the treatment approach "Robin" (standardized manual and smartphone App) for adolescents with high risk for developing a psychotic disorder. The manual is targeting at risksymptoms, comorbid disorders, improvement of quality of life and daily functioning. The therapy modules are based on evidence based treatment strategies in adults with a high risk and recommendations for adolescents with first episodes of psychosis. It follows the guidelines on early intervention in clinical psychosis high risk states of the European Association for Psychiatry. The intervention also includes a smartphone application for supporting the patients between sessions. This application targets real-time symptom assessment, medication adherence, and provides coping strategies for dealing with symptoms of psychosis and daily life hurdles.
S33. ETRO -A PROSPECTIVE FOLLOW-UP STUDY OF THE COMBINED TREATMENT APPROACH "ROBIN" FOR ADOLESCENTS WITH HIGH RISK FOR DEVELOPING

Methods:
The clinical intervention study ETRo is designed as a naturalistic controlled trial. The goal is to compare efficacy of a 16-week intervention in patients with at-risk symptoms (age range 13-18) with an active control group (treatment as usual). Power calculations conducted in collaboration with a statistician determined the recruitment goal of 30 participants in the treatment condition. Participants from a former early recognition study (N=62, Age: 13-18 years, Ø 15.06) are included for the control condition. For the intervention condition, help seeking adolescents with APS-Symptoms, aged 13-18, are being recruited during a three year time period. Within this prospective study, at-risk symptoms and data for comorbid symptoms, functioning, self-efficacy, and quality of life are collected at six time points (baseline, during the treatment period, immediately after intervention and 6, 12 and 24 months later). Results: Since August 2017, first participants have been included and their treatment has started. In Florence, we will present our first results. This will include implementation of the treatment program and first findings of treatment period. Discussion: Even though young patients with at-risk symptoms may profit best of specialised treatment approaches, little is known about age-appropriate treatment strategies in this vulnerable age group. This is one of the first controlled trials to test the efficacy of a specific treatment program for minor patients with attenuated psychotic symptoms.
S34. DEVELOPMENTAL TRAJECTORIES OF PSYCHOTIC EXPERIENCES AND THEORY OF MIND IN 11-YEAR-OLD OFFSPRING OF PARENTS WITH SCHIZOPHRENIA OR BIPOLAR DISORDER
